glp 1 agonist in ckd GLP-1 Receptor Agonists and Kidney Protection GLP-1 receptor agonists and next-generation
Description
10.5772/63144 31 KalraS.BhattacharyaS.KapoorN
Gamble J-M, Chibrikov E, Midodzi WK, Twells LK, Majumdar SR
Highlights of 2024: The year the obesity market took shape The market for anti-obesity medications (AOMs) reached a major milestone in 2024 with global spend exceeding $30Bn for the first time, an over ten-fold increase since 2020
Albiglutide has a half-life of 120 h and dulaglutide has a half-life of 90 h, therefore administration is only required once a week [26]
Glucagon-like peptide-1 receptor agonist treatment with semaglutide in type 1 diabetes
